In vitro antibiofilm efficacy of ertapenem, tobramycin, and moxifloxacin against biofilms grown in a glass bead or CDC Biofilm Reactor®
PLOS ONE · 10.02.2025 · 20 (2) · e0318487
DOI: 10.1371/journal.pone.0318487 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 10.02.2025. Verfasst von Annika L Gilmore und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Utah, Salt Lake City, Utah, United States of America. Hauptthemen laut MEDLINE: Biofilms, Tobramycin, Anti-Bacterial Agents, Fluoroquinolones. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CDMRP, Congressionally Directed Medical Research Programs.
Abstract (Originalsprache)
Laboratory grown biofilms are used to simulate bacterial growth in diverse environmental conditions and screen the effectiveness of anti-biofilm therapies. Recently, we developed a glass bead biofilm reactor that utilizes low broth volume to provide high-throughput biofilm growth for testing and translation across the research continuum (e.g., benchtop assays to preclinical models). Bioburden per mm 2 surface area of Staphylococcus aureus and Pseudomonas aeruginosa biofilms were comparable on beads and CDC Biofilm Reactor® coupons. In this study, we hypothesized that biofilms grown on beads would be more susceptible to ertapenem, moxifloxacin, and tobramycin than those grown on coupons. Results indicated a significant reduction in S. aureus bioburden on glass beads compared to glass coupons following treatment with ertapenem ( p = 0.005) and tobramycin ( p = 0.014). P. aeruginosa biofilms had smaller differences in antibiotic response between the two systems. There was a significantly greater reduction in bead P. aeruginosa biofilm than coupon when treated with tobramycin ( p = 0.035). This work offered insight into how the bead biofilm reactor could be used as a tool for antibiotic screening and translation across the continuum of in vitro to in vivo systems that support development of antimicrobial technology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, University of Utah, Salt Lake City, Utah, United States of America.
- Department of Orthopaedics, University of Utah, Salt Lake City, Utah, United States of America.
- Bone and Biofilm Research Lab, University of Utah, Salt Lake City, Utah, United States of America.
- Depuy Synthes, West Chester, Pennsylvania, United States of America.
- Department of Pathology, University of Utah, Salt Lake City, Utah, United States of America.
- Department of Physical Medicine and Rehabilitation, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.
ORCID-Profile: Annika L Gilmore, Travis Martinez
Förderung
- CDMRP
- Congressionally Directed Medical Research Programs
Zitieren
APA
Gilmore, A. L., Vu, H., Martinez, T., Peniata, L., Kawaguchi, B., Armbruster, D. A., Ashton, N. N., & Williams, D. L. (2025). In vitro antibiofilm efficacy of ertapenem, tobramycin, and moxifloxacin against biofilms grown in a glass bead or CDC Biofilm Reactor®. PLOS ONE, 20(2), e0318487. https://doi.org/10.1371/journal.pone.0318487
Vancouver
Gilmore AL, Vu H, Martinez T, Peniata L, Kawaguchi B, Armbruster DA, et al. In vitro antibiofilm efficacy of ertapenem, tobramycin, and moxifloxacin against biofilms grown in a glass bead or CDC Biofilm Reactor®. PLOS ONE. 2025;20(2):e0318487. doi:10.1371/journal.pone.0318487
BibTeX
@article{Gilmore2025,
author = {Gilmore, Annika L and Vu, Helena and Martinez, Travis and Peniata, Lousili and Kawaguchi, Brooke and Armbruster, David A and Ashton, Nicholas N and Williams, Dustin L},
title = {In vitro antibiofilm efficacy of ertapenem, tobramycin, and moxifloxacin against biofilms grown in a glass bead or CDC Biofilm Reactor®},
journal = {PLOS ONE},
year = {2025},
volume = {20},
number = {2},
pages = {e0318487},
doi = {10.1371/journal.pone.0318487}
}
EUVIMED